Publications

Journal of the National Cancer Institute

Role of breast cancer resistance protein in the bioavailability and fetal penetration of topotecan.

18-10-2000

Cancer research

Extensive contribution of the multidrug transporters P-glycoprotein and Mrp1 to basal drug resistance.

15-10-2000

The Journal of clinical investigation

Multidrug resistance protein 1 protects the choroid plexus epithelium and contributes to the blood-cerebrospinal fluid barrier.

01-02-2000

The Journal of clinical investigation

Absence or pharmacological blocking of placental P-glycoprotein profoundly increases fetal drug exposure.

01-11-1999

Cancer research

The mouse Bcrp1/Mxr/Abcp gene: amplification and overexpression in cell lines selected for resistance to topotecan, mitoxantrone, or doxorubicin.

01-09-1999

British journal of pharmacology

Role of blood-brain barrier P-glycoprotein in limiting brain accumulation and sedative side-effects of asimadoline, a peripherally acting analgaesic drug.

01-05-1999

Advanced drug delivery reviews

P-Glycoprotein, a gatekeeper in the blood-brain barrier.

05-04-1999

The Journal of pharmacology and experimental therapeutics

Comparative pharmacokinetics of vinblastine after a 96-hour continuous infusion in wild-type mice and mice lacking mdr1a P-glycoprotein.

01-04-1999

British journal of cancer

Increased accumulation of doxorubicin and doxorubicinol in cardiac tissue of mice lacking mdr1a P-glycoprotein.

01-01-1999

Journal of the National Cancer Institute

Availability of PSC833, a substrate and inhibitor of P-glycoproteins, in various concentrations of serum.

05-08-1998

Hepatology (Baltimore, Md.)

Hepatocyte-specific expression of the human MDR3 P-glycoprotein gene restores the biliary phosphatidylcholine excretion absent in Mdr2 (-/-) mice.

01-08-1998

The Journal of clinical investigation

Drug export activity of the human canalicular multispecific organic anion transporter in polarized kidney MDCK cells expressing cMOAT (MRP2) cDNA.

01-04-1998

International journal of clinical pharmacology and therapeutics

Pharmacological insights from P-glycoprotein knockout mice.

01-01-1998

The Journal of clinical investigation

Full blockade of intestinal P-glycoprotein and extensive inhibition of blood-brain barrier P-glycoprotein by oral treatment of mice with PSC833.

15-11-1997

Trends in genetics : TIG

Genetic dissection of the function of mammalian P-glycoproteins.

01-06-1997

Seminars in cancer biology

The physiological function of drug-transporting P-glycoproteins.

01-06-1997

Proceedings of the National Academy of Sciences of the United States of America

Normal viability and altered pharmacokinetics in mice lacking mdr1-type (drug-transporting) P-glycoproteins.

15-04-1997

Proceedings of the National Academy of Sciences of the United States of America

Limited oral bioavailability and active epithelial excretion of paclitaxel (Taxol) caused by P-glycoprotein in the intestine.

04-03-1997

British journal of cancer

Enhanced oral bioavailability of paclitaxel in mice treated with the P-glycoprotein blocker SDZ PSC 833.

01-01-1997

British journal of pharmacology

Substantial excretion of digoxin via the intestinal mucosa and prevention of long-term digoxin accumulation in the brain by the mdr 1a P-glycoprotein.

01-11-1996

The Journal of neuroscience : the official journal of the Society for Neuroscience

Peripheral neuropathy in mice transgenic for a human MDR3 P-glycoprotein mini-gene.

15-10-1996

Journal of the National Cancer Institute

Altered pharmacokinetics of vinblastine in Mdr1a P-glycoprotein-deficient Mice.

17-07-1996

European journal of cancer (Oxford, England : 1990)

What have we learnt thus far from mice with disrupted P-glycoprotein genes?

01-06-1996

The Journal of clinical investigation

P-glycoprotein in the blood-brain barrier of mice influences the brain penetration and pharmacological activity of many drugs.

01-06-1996

The Journal of clinical investigation

Basolateral localization and export activity of the human multidrug resistance-associated protein in polarized pig kidney cells.

01-03-1996

Gastroenterology

Regulation of protein secretion into bile: studies in mice with a disrupted mdr2 p-glycoprotein gene.

01-12-1995

The Journal of clinical investigation

Absence of the mdr1a P-Glycoprotein in mice affects tissue distribution and pharmacokinetics of dexamethasone, digoxin, and cyclosporin A.

01-10-1995

European journal of cancer (Oxford, England : 1990)

Multidrug resistance and the role of P-glycoprotein knockout mice.

01-07-1995

Biochimica et biophysica acta

Characterization of the promoter region of the human MDR3 P-glycoprotein gene.

14-03-1995

FEBS letters

The human MDR3 P-glycoprotein promotes translocation of phosphatidylcholine through the plasma membrane of fibroblasts from transgenic mice.

14-11-1994

Laboratory investigation; a journal of technical methods and pathology

Tissue distribution of the human MDR3 P-glycoprotein.

01-11-1994

Cell

Disruption of the mouse mdr1a P-glycoprotein gene leads to a deficiency in the blood-brain barrier and to increased sensitivity to drugs.

20-05-1994

Cell

Homozygous disruption of the murine mdr2 P-glycoprotein gene leads to a complete absence of phospholipid from bile and to liver disease.

05-11-1993

Pharmacology & therapeutics

Classical and novel forms of multidrug resistance and the physiological functions of P-glycoproteins in mammals.

01-11-1993

International journal of cancer

Binding properties of monoclonal antibodies recognizing external epitopes of the human MDR1 P-glycoprotein.

30-09-1993

The Journal of biological chemistry

N-glycosylation and deletion mutants of the human MDR1 P-glycoprotein.

05-04-1993

Seminars in cancer biology

Multidrug resistance mediated by P-glycoproteins.

01-08-1991

Cancer research

Characterization of the human MDR3 P-glycoprotein and its recognition by P-glycoprotein-specific monoclonal antibodies.

15-05-1991

Bone marrow transplantation

Resistance to natural products in leukemia.

01-07-1990

Role of breast cancer resistance protein in the bioavailability and fetal penetration of topotecan.

Extensive contribution of the multidrug transporters P-glycoprotein and Mrp1 to basal drug resistance.

Multidrug resistance protein 1 protects the choroid plexus epithelium and contributes to the blood-cerebrospinal fluid barrier.

Absence or pharmacological blocking of placental P-glycoprotein profoundly increases fetal drug exposure.

The mouse Bcrp1/Mxr/Abcp gene: amplification and overexpression in cell lines selected for resistance to topotecan, mitoxantrone, or doxorubicin.

Role of blood-brain barrier P-glycoprotein in limiting brain accumulation and sedative side-effects of asimadoline, a peripherally acting analgaesic drug.

P-Glycoprotein, a gatekeeper in the blood-brain barrier.

Comparative pharmacokinetics of vinblastine after a 96-hour continuous infusion in wild-type mice and mice lacking mdr1a P-glycoprotein.

Increased accumulation of doxorubicin and doxorubicinol in cardiac tissue of mice lacking mdr1a P-glycoprotein.

Availability of PSC833, a substrate and inhibitor of P-glycoproteins, in various concentrations of serum.

Hepatocyte-specific expression of the human MDR3 P-glycoprotein gene restores the biliary phosphatidylcholine excretion absent in Mdr2 (-/-) mice.

Drug export activity of the human canalicular multispecific organic anion transporter in polarized kidney MDCK cells expressing cMOAT (MRP2) cDNA.

Pharmacological insights from P-glycoprotein knockout mice.

Full blockade of intestinal P-glycoprotein and extensive inhibition of blood-brain barrier P-glycoprotein by oral treatment of mice with PSC833.

Genetic dissection of the function of mammalian P-glycoproteins.

The physiological function of drug-transporting P-glycoproteins.

Normal viability and altered pharmacokinetics in mice lacking mdr1-type (drug-transporting) P-glycoproteins.

Limited oral bioavailability and active epithelial excretion of paclitaxel (Taxol) caused by P-glycoprotein in the intestine.

Enhanced oral bioavailability of paclitaxel in mice treated with the P-glycoprotein blocker SDZ PSC 833.

Substantial excretion of digoxin via the intestinal mucosa and prevention of long-term digoxin accumulation in the brain by the mdr 1a P-glycoprotein.

Peripheral neuropathy in mice transgenic for a human MDR3 P-glycoprotein mini-gene.

Altered pharmacokinetics of vinblastine in Mdr1a P-glycoprotein-deficient Mice.

What have we learnt thus far from mice with disrupted P-glycoprotein genes?

P-glycoprotein in the blood-brain barrier of mice influences the brain penetration and pharmacological activity of many drugs.

Basolateral localization and export activity of the human multidrug resistance-associated protein in polarized pig kidney cells.

Regulation of protein secretion into bile: studies in mice with a disrupted mdr2 p-glycoprotein gene.

Absence of the mdr1a P-Glycoprotein in mice affects tissue distribution and pharmacokinetics of dexamethasone, digoxin, and cyclosporin A.

Multidrug resistance and the role of P-glycoprotein knockout mice.

Characterization of the promoter region of the human MDR3 P-glycoprotein gene.

The human MDR3 P-glycoprotein promotes translocation of phosphatidylcholine through the plasma membrane of fibroblasts from transgenic mice.

Tissue distribution of the human MDR3 P-glycoprotein.

Disruption of the mouse mdr1a P-glycoprotein gene leads to a deficiency in the blood-brain barrier and to increased sensitivity to drugs.

Homozygous disruption of the murine mdr2 P-glycoprotein gene leads to a complete absence of phospholipid from bile and to liver disease.

Classical and novel forms of multidrug resistance and the physiological functions of P-glycoproteins in mammals.

Binding properties of monoclonal antibodies recognizing external epitopes of the human MDR1 P-glycoprotein.

N-glycosylation and deletion mutants of the human MDR1 P-glycoprotein.

Multidrug resistance mediated by P-glycoproteins.

Characterization of the human MDR3 P-glycoprotein and its recognition by P-glycoprotein-specific monoclonal antibodies.

Resistance to natural products in leukemia.

This site uses cookies